Clearmind Medicine (CMND) Stock Price, News & Analysis

Company Overview

Clearmind Medicine, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates. Among these is an iboga alkaloid analog designed to treat neuropathic pain and opioid use disorder, as well as a series of next-generation psychoplastogens for major depressive disorder and post-traumatic stress disorder. The company’s research programs also explore applications in mild traumatic brain injury and Alzheimer’s-type dementias, with the goal of delivering therapies that restore neural circuitry and improve cognitive function.

Headquartered in North America, Clearmind Medicine operates research facilities and partnerships across Canada and the United States. The company collaborates with academic institutions and contract research organizations to advance its drug candidates through toxicology studies and human trials. By combining proprietary medicinal chemistry with established preclinical models, Clearmind seeks to streamline development timelines and establish differentiated therapeutic profiles.

Clearmind’s leadership team comprises professionals with deep expertise in neuroscience, clinical development and regulatory affairs. The company’s board and scientific advisors include experts in psychopharmacology, neurology and drug development strategy, reflecting a commitment to rigorous science and commercial execution. As a Nasdaq-listed entity, Clearmind Medicine continues to expand its research collaborations and augment its pipeline in pursuit of new treatments for underserved neurological and psychiatric indications.

Key Stats

• Today's Range: $2.03 to $2.15
• 50-Day Range: $2.03 to $7.12
• 52-Week Range: $2.00 to $524.00
• Volume: 95,905 shs
• Average Volume: 925,828 shs
• Market Capitalization: $2.07 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Clearmind Medicine Stock Analysis - MarketRank™

Clearmind Medicine scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Clearmind Medicine.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Clearmind Medicine is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Clearmind Medicine is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Clearmind Medicine has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

19.96% of the float of Clearmind Medicine has been sold short.

Short Interest Ratio / Days to Cover

Clearmind Medicine has a short interest ratio ("days to cover") of 0.25, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Clearmind Medicine has recently decreased by 41.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clearmind Medicine does not currently pay a dividend.

Dividend Growth

Clearmind Medicine does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.21

News Sentiment

Clearmind Medicine has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Clearmind Medicine this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for CMND on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $205,925.00 in company stock, which represents 9.9452% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Clearmind Medicine insiders have bought 174.61% more of their company's stock than they have sold. Specifically, they have bought $323,858.00 in company stock and sold $117,933.00 in company stock.

Percentage Held by Institutions

96.05% of the stock of Clearmind Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/15/2026
• Today: 7/13/2026
• Fiscal Year End: 10/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMND
• CIK: 1892500
• Web: www.clearmindmedicine.com
• Phone: 604-260-1566
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($139.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -143.79%
• Return on Assets: -88.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.79
• Quick Ratio: 4.79

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.41 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 1,020,000
• Free Float: N/A
• Market Cap: $2.07 million
• Optionable: Not Optionable
• Beta: 0.74